Savara Inc. (NASDAQ:SVRA) shareholders (or potential shareholders) will be happy to see that the Independent Director, David Ramsay, recently bought a whopping US$1m worth of stock, at a price of US$1 ...
The sale was entirely from direct ownership and resulted from the exercise of 580,187 options; 185,659 shares were withheld for tax obligations. The 394,528-share sale is materially larger than ...
Savara ( (SVRA)) has issued an update. On June 4, 2026, Savara’s stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the pool of shares available for equity awards by 18, ...
Savara Inc. (NASDAQ:SVRA) on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of ...
Potential Savara Inc. (NASDAQ:SVRA) shareholders may wish to note that the Independent Director, David Ramsay, recently bought US$142k worth of stock, paying US$1.42 for each share. While that's a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results